Literature DB >> 28197525

HSD11B1 rs846908 polymorphisms and tacrolimus concentrations: quantum chemical analysis and implication in patients with renal transplantation.

Beuy Joob1, Viroj Wiwanitkit2.   

Abstract

Entities:  

Keywords:  Kidney; Polymorphism; Tacrolimus; Transplantation

Year:  2016        PMID: 28197525      PMCID: PMC5295653     

Source DB:  PubMed          Journal:  J Nephropharmacol        ISSN: 2345-4202


× No keyword cloud information.

Implication for health policy/practice/research/medical education:

Tacrolimus is a widely used immunosuppressive drug for post renal transplantation. The concentration of tacrolimus is important for success in management of renal recipients. The effect of genetic polymorphism on the concentration of tacrolimus is very interesting. Here, the author studied the SD11B1 rs846908 polymorphisms and tacrolimus concentrations by quantum chemical analysis. It can be seen that the AA + AA polymorphism results in less finalized tacrolimus concentration comparing to GG + GA polymorphism.

Introduction

Renal transplantation is the therapeutic of choice for the end stage renal disease. With advanced immunosuppressive drug, the outcome of renal transplantation becomes favorable in the present day (1). Tacrolimus is a widely used immunosuppressive drug for post-renal transplantation (2). The concentration of tacrolimus is important for success in management of the patient. The effect of genetic polymorphism on the concentration of tacrolimus is very interesting (3). Of several genes, the 11beta-hydroxysteroid dehydrogenase type 1 (HSD11B1) is widely discussed at present (4). Here, the author studied the HSD11B1 rs846908 polymorphisms and tacrolimus concentrations by quantum chemical analysis. It can be seen that the AA + AA polymorphism results in less finalized tacrolimus concentration comparing to GG + GA polymorphism.

Materials and Methods

This work is designed as a quantum chemistry analysis using mathematical modeling study. The basic consideration is HSD11B1 gene is the origin for further proteinogenesis and subsequence further biological process and expression. The final outcome is the tacrolimus concentration. The assumption is there is a direct linkage, without any intermediate interruption, from HSD11B1 gene to tacrolimus concentration. The amount of HSD11B1 gene is therefore the determinant of tacrolimus concentration. This process can be seen in any genetic polymorphism of HSD11B1. To calculate, the final concentration of tacrolimus in mutation, standard quantum chemical analysis is used. This is the same concept as published in previous publications (5,6). As a primary assumption, in wild type, the outcome concentration of tacrolimus is firstly assigned to be “X” mol per gram of original HSB11B1 rs846908. The variability in this modeling study is the change in substrate, due to polymorphism. The studied polymorphisms are AA + AA and GG + GA.

Results

The results from this study are shown in Table 1. It can be seen that the polymorphism GG + GA has a higher amount per mol than AA + AA. Therefore, predicted outcome concentration of tacrolimus is higher in polymorphism GG + GA. The predicted concentration of tacrolimus in AA + AA is 1.0889 time more than that of GG + GA.
Table 1

Predicted outcome concentration of tacrolimus

Types Amount per mol of HSD11B1 rs846908 (g) predicted outcome concentration of tacrolimus (mol)
AA + AA540.5068540.5068X
GG + GA588.5050588.5050X

Discussion

Effect of HSD11B1 gene polymorphism is mentioned in several clinical problems in medicine (4,7,8), moreover its effect on renal transplantation and the concentration of tacrolimus is also mentioned. Recently, a model study could reveal the importance of glucocorticoid and fat in determining dosage requirement of tacrolimus in post renal transplantation status (9). Hence, the role of HSD11B1 gene polymorphism is very interesting. Here, the authors assess the interrelationship between HSD11B1 rs846908 polymorphisms and tacrolimus concentration. In this study, it can be found that GG + GA polymorphism result in more amount or higher concentration of tacrolimus than AA + AA polymorphism. This is concordant with the recent clinical finding by Liu et al (4). Nevertheless, in the report by Liu et al, the concentration of tacrolimus in case of GG + GG polymorphism is about 1.3648 times higher than that of AA + AA polymorphism. This can confirm that, other factors like, other genetic polymorphisms, epigenetic factors, other concurrent diseases, underlying physiology and pathology of the kidney, still existed to determine the outcome of tacrolimus concentration.

Conclusion

Tacrolimus is a widely used immunosuppressive drug for post renal transplantation. The concentration of tacrolimus is important for success in management of renal recipients. The effect of genetic polymorphism on the concentration of tacrolimus is very interesting. Here, the author studied the SD11B1 rs846908 polymorphisms and tacrolimus concentrations by quantum chemical analysis. It can be seen that the AA + AA polymorphism results in less finalized tacrolimus concentration comparing to GG + GA polymorphism.

Authors’ contribution

VW and BJ wrote the manuscript equally.

Conflicts of interest

The author declared no competing interests.

Ethical considerations

Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by authors.

Funding/Support

None.
  9 in total

Review 1.  Primary Care of the Solid Organ Transplant Recipient.

Authors:  Christopher J Wong; Genevieve Pagalilauan
Journal:  Med Clin North Am       Date:  2015-09       Impact factor: 5.456

2.  An explanation in nanostructure level based on the view of energy change for G333d mutation relating to drug resistance in HIV-1 reverse transcriptase.

Authors:  V Wiwanitkit
Journal:  Indian J Med Microbiol       Date:  2008 Apr-Jun       Impact factor: 0.985

Review 3.  Pharmacogenetics and immunosuppressive drugs.

Authors:  Karolína Hronová; Martin Šíma; Svatopluk Světlík; Olga Matoušková; Ondřej Slanař
Journal:  Expert Rev Clin Pharmacol       Date:  2014-10-10       Impact factor: 5.045

4.  Associations of HSD11B1 polymorphisms with tacrolimus concentrations in Chinese renal transplant recipients with prednisone combined therapy.

Authors:  Xiaoman Liu; Jiali Li; Qian Fu; Shu Liu; Yu Zhang; Xueding Wang; Hongyang Wang; Jun Li; Chen Zhu; Changxi Wang; Min Huang
Journal:  Drug Metab Dispos       Date:  2015-01-13       Impact factor: 3.922

Review 5.  Tacrolimus prolonged release (Envarsus®): a review of its use in kidney and liver transplant recipients.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

6.  Association between ins4436A in 11β-hydroxysteroid dehydrogenase type 1 gene and essential hypertension in Polish population.

Authors:  Paulina Hejduk; Agata Sakowicz; Tadeusz Pietrucha
Journal:  Postepy Hig Med Dosw (Online)       Date:  2015-11-17       Impact factor: 0.270

7.  Analysis of binding energy activity of imatinib and Abl tyrosine kinase domain based on simple consideration for conformational change: An explanation for variation in imatinib effect in mutated type.

Authors:  V Wiwanitkit
Journal:  Indian J Cancer       Date:  2009 Oct-Dec       Impact factor: 1.224

8.  Improved prediction of tacrolimus concentrations early after kidney transplantation using theory-based pharmacokinetic modelling.

Authors:  Elisabet Størset; Nick Holford; Stefanie Hennig; Troels K Bergmann; Stein Bergan; Sara Bremer; Anders Åsberg; Karsten Midtvedt; Christine E Staatz
Journal:  Br J Clin Pharmacol       Date:  2014-09       Impact factor: 4.335

9.  Gender-dependent association of HSD11B1 single nucleotide polymorphisms with glucose and HDL-C levels.

Authors:  Luciane Viater Turek; Neiva Leite; Ricardo Lehtonen Rodrigues Souza; Jovana Karoline Lima; Gerusa Eisfeld Milano; Luciana da Silva Timossi; Ana Claudia Vecchi Osiecki; Raul Osiecki; Lupe Furtado Alle
Journal:  Genet Mol Biol       Date:  2014-09       Impact factor: 1.771

  9 in total
  6 in total

1.  Association of FTO rs9939609 with Obesity.

Authors:  Sora Yasri; Viroj Wiwanitkit
Journal:  Med Princ Pract       Date:  2018-05-30       Impact factor: 1.927

2.  Estimated change of COVID-19 vaccine efficacy due to omicron variant SARS CoV2.

Authors:  Rujittika Mungmunpuntipantip; Viroj Wiwanitkit
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2022-04-15

3.  Aggressive Behavior and Short-Long Polymorphisms of Monoamine Oxidase A: An Example of Effect of Genetic Molecular Mass Change in Psychological Medicine.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  Indian J Psychol Med       Date:  2017 Nov-Dec

4.  WWOX rs11644322 Polymorphism, Gemcitabine, and Pancreatic Cancer.

Authors:  Sora Yasri; Viroj Wiwanitkit; Beuy Joob
Journal:  Indian J Med Paediatr Oncol       Date:  2017 Jul-Sep

5.  Angiotensin-converting enzyme G2350A gene polymorphisms and hypertension among patients with intracerebral hemorrhage.

Authors:  Beuy Joob; Viroj Wiwanitkit
Journal:  J Taibah Univ Med Sci       Date:  2019-10-11

6.  Methylenetetrahydrofo late reductase C677T polymorphism and schizophrenia: Effect of molecular change.

Authors:  Sora Yasri; Viroj Wiwanitkit
Journal:  J Res Med Sci       Date:  2018-03-27       Impact factor: 1.852

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.